The latest issue of Compass, our research publication, is now available online. This fall 2015 issue covers our 2015 SMA Researcher Meeting. The researcher meeting is held each year as part of our Annual SMA Conference. It is the largest research meeting in the world focused on SMA, where about 300 basic researchers, drug developers, […]
Fall 2015 Issue of Compass Highlights SMA Researcher Meeting Read More »
Members of Cure SMA’s Medical Advisory Council (MAC) have gathered in Chicago for two days of meetings to set the agenda for the care of SMA individuals and families. Our MAC is chaired by Mary Schroth, MD, a leading pulmonologist, and professor of pediatrics. The MAC is one of the most highly respected bodies of
Cure SMA Medical Advisory Council Meets in Chicago Read More »
We need your help in contacting your Senators to tell them that legislation promoting innovation and research is extremely important to you and that the discovery of the next generation of cures and treatments for disease needs to start now! We are concerned about Congress’ lack of progress on the 21st Century Cures legislation (H.R.
Tell Your Senator to Support Innovations for Healthier Americans Read More »
Cure SMA is pleased to announce the creation of a new chapter in northern New Jersey, serving families and supporters with zip codes starting with 07, 085, 086, 087, and 088. Led by chairpersons Kara Hartnett (family support), Anna Pham (fundraising), and Zainab Jaffar (communications), the chapter is excited to begin helping families throughout their
Cure SMA Welcomes the North Jersey Chapter Read More »
Cure SMA President Kenneth Hobby was a featured panelist at Partnering for Cures, a conference convened by the Milken Institute’s FasterCures initiative. At the event, over 700 research innovators—including senior government officials, patient advocates, scientists, major investors, industry CEOs and philanthropists—gathered to discuss some of the most common barriers to speeding up innovation in medical
Cytokinetics, in collaboration with Astellas, has announced further details about a planned Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA). CK-2127107 is a skeletal muscle activator. The drug has the potential to improve muscle function, either alone or in combination with other drugs. We are excited to see the continued
Cytokinetics Announces New Details on Upcoming Phase 2 Trial Read More »
Cure SMA, along with collaborators from Biogen and the SMA Foundation, have published a paper in the journal BMC Neurology. Over the past year, we’ve completed 16 focus group sessions and 37 interviews in the US with 96 participants including: 21 with individuals with SMA; 64 parents of individuals affected by SMA; and 11 clinicians
Cure SMA Publishes Journal Article on the Patient Voice Read More »
Cure SMA recently received a donation of 10 special tomato feeder seats from Jadon’s Hope Foundation. These were immediately sent out to families who were on a waiting list for a feeder seat. Thanks to Jadon’s Hope, these familes no longer have to wait! Jadon’s Hope Foundation was created by Tony and Kristin Burks in
Jadon’s Hope Foundation Donates 10 New Tomato Feeder Seats Read More »
Cure SMA-funded researchers Rebecca Hurst Davis and Kathy Swoboda have published a paper, “Responses to Fasting and Glucose Loading in a Cohort of Well Children with Spinal Muscular Atrophy Type II” in the journal Pediatrics. Elizabeth A. Miller and Ren Zhe Zhang also co-authored the paper. This study was funded by an initial $50,000 Cure
Cure SMA-Funded Researchers Publish Paper in Journal Pediatrics Read More »
Isis Pharmaceuticals, Inc. announced that it has initiated an open-label extension study, SHINE. The SHINE study provides ISIS-SMNRx to infants and children with spinal muscular atrophy (SMA) who have completed their participation in the Phase 3 ENDEAR and CHERISH studies and are eligible to participate in SHINE. All patients in the SHINE study will receive
Isis Pharmaceuticals Announces SHINE, an Open-Label Extension Study Read More »
